scispace - formally typeset
M

Michael Greenall

Researcher at John Radcliffe Hospital

Publications -  17
Citations -  3192

Michael Greenall is an academic researcher from John Radcliffe Hospital. The author has contributed to research in topics: Breast cancer & Metastasis. The author has an hindex of 15, co-authored 17 publications receiving 3114 citations.

Papers
More filters
Journal Article

Association of Macrophage Infiltration with Angiogenesis and Prognosis in Invasive Breast Carcinoma

TL;DR: Analysis of macrophage infiltration in invasive breast carcinomas indicates a role for macrophages in angiogenesis and prognosis in breast cancer and that this cell type may represent an important target for immunoinhibitory therapy in Breast cancer.
Journal ArticleDOI

Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

TL;DR: The results suggest that angiogenesis is closely linked to metastasis, that it is acquired at a critical density of vessels, and that this process occurs as tumours enlarge or become more poorly differentiated.
Journal ArticleDOI

Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival.

TL;DR: In this article, microvessel density was measured in a series of well characterised node negative breast carcinomas to evaluate angiogenesis as a prognostic marker and assess its relationship to epidermal growth factor receptor (EGFR) and estrogen receptor (ER), which have previously been reported to be of value.
Journal ArticleDOI

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.

TL;DR: Epidermal growth factor receptor (EGFR) and estrogen receptor (ER) were assayed by ligand binding in tumors from 370 patients with primary breast carcinoma with a median follow up of 18 months, and there was a highly significant inverse relationship between EGFR and ER.
Journal ArticleDOI

High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.

TL;DR: The results show that serum YKL-40 in patients with primary breast cancer at time of operation is only elevated in a small group of patients, but these patients have a shorter recurrence free interval.